Uquifa is the API division of Vivimed Labs. Uquifa is a manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates for the pharmaceutical Industry. Operates 3 manufacturing sites, 2 in Spain and 1 in Mexico, which operates under cGMP conditions and has been inspected and approved by major Pharmaceutical Companies and Regulatory Authorities, including the US FDA.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

ADDITIONAL US$ 4 MILLION RECEIVED FOR NEXT DEVELOPMENT STEPS OF MEDINCELL'S 6-MONTH ACTIVE INJECTABLE BIORESORBABLE SUBCUTANEOUS CONTRACEPTIVE

MedinCell | December 01, 2022

news image

MedinCell has received an additional US$ 4 million payment from the Bill & Melinda Gates Foundation This amount is intended to finance the next steps of MedinCell’s program mdc-WWM in readiness to initiate the first clinical trial end of 2023 It follows US$ 11,8 million already received as part of the two successive grants for a total of up to US$ 22,5 million from the Bill & Melinda Gates Foundation to finance the development of the program up to phas...

Read More

Pharmacy Market

VALEMETOSTAT NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR TREATMENT OF PATIENTS WITH ADULT T-CELL LEUKEMIA/LYMPHOMA

Daiichi Sankyo | December 29, 2021

news image

Daiichi Sankyo Company, Limited announced that it has submitted a New Drug Application to Japan’s Ministry of Health, Labour and Welfare for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T-cell leukemia/lymphoma. ATL is a rare and aggressive type of peripheral T-cell lymphoma that occurs with greater frequency in parts of Japan and other regions.1,2 Patients with ATL face a poor prognosi...

Read More

Pharma Tech

PALATIN ANNOUNCES INTENT TO EFFECT REVERSE STOCK SPLIT

Palatin Technologies, Inc. | August 20, 2022

news image

Palatin Technologies, Inc. a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that it intends to effect a 1-for-25 reverse split of its issued and outstanding common stock. The Reverse Stock Split will become effective as of 5:00 p.m. Eastern Time on August 30, 2022 and the Company's common stock is expected to begin trading on a split-adjusted basis when t...

Read More

PHARMACY MARKET

CYTEL CONTINUES EXPANSION OF MARKET ACCESS AND MEDICAL COMMUNICATION CAPABILITIES WITH THE ACQUISITION OF CO.FAKTOR

Business Wire | September 28, 2023

news image

Cytel Inc., provider of quantitative insights and health data analytics to leaders in the life sciences, has acquired the Berlin-based company co.faktor GmbH with its dedicated healthcare consultancy services co.value® (market access), co.medical® (medical communications), and co.patient® (patient relations) concentrations. As a result, Cytel’s services for biopharma commercializa...

Read More
news image

Pharma Tech

ADDITIONAL US$ 4 MILLION RECEIVED FOR NEXT DEVELOPMENT STEPS OF MEDINCELL'S 6-MONTH ACTIVE INJECTABLE BIORESORBABLE SUBCUTANEOUS CONTRACEPTIVE

MedinCell | December 01, 2022

MedinCell has received an additional US$ 4 million payment from the Bill & Melinda Gates Foundation This amount is intended to finance the next steps of MedinCell’s program mdc-WWM in readiness to initiate the first clinical trial end of 2023 It follows US$ 11,8 million already received as part of the two successive grants for a total of up to US$ 22,5 million from the Bill & Melinda Gates Foundation to finance the development of the program up to phas...

Read More
news image

Pharmacy Market

VALEMETOSTAT NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR TREATMENT OF PATIENTS WITH ADULT T-CELL LEUKEMIA/LYMPHOMA

Daiichi Sankyo | December 29, 2021

Daiichi Sankyo Company, Limited announced that it has submitted a New Drug Application to Japan’s Ministry of Health, Labour and Welfare for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T-cell leukemia/lymphoma. ATL is a rare and aggressive type of peripheral T-cell lymphoma that occurs with greater frequency in parts of Japan and other regions.1,2 Patients with ATL face a poor prognosi...

Read More
news image

Pharma Tech

PALATIN ANNOUNCES INTENT TO EFFECT REVERSE STOCK SPLIT

Palatin Technologies, Inc. | August 20, 2022

Palatin Technologies, Inc. a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that it intends to effect a 1-for-25 reverse split of its issued and outstanding common stock. The Reverse Stock Split will become effective as of 5:00 p.m. Eastern Time on August 30, 2022 and the Company's common stock is expected to begin trading on a split-adjusted basis when t...

Read More
news image

PHARMACY MARKET

CYTEL CONTINUES EXPANSION OF MARKET ACCESS AND MEDICAL COMMUNICATION CAPABILITIES WITH THE ACQUISITION OF CO.FAKTOR

Business Wire | September 28, 2023

Cytel Inc., provider of quantitative insights and health data analytics to leaders in the life sciences, has acquired the Berlin-based company co.faktor GmbH with its dedicated healthcare consultancy services co.value® (market access), co.medical® (medical communications), and co.patient® (patient relations) concentrations. As a result, Cytel’s services for biopharma commercializa...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us